Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting
- 61 Downloads
OnabotulinumtoxinA (OnabotA) appears to be an effective prophylactic treatment for chronic migraine (CM), but its use in patients with episodic migraine (EM) has been little explored. We set out to assess the clinical efficacy of OnabotA in a real-life setting, focusing particularly on EM patients.
This is a longitudinal, prospective, single-center analysis of 115 migraine patients [70 with CM, 21 with low-frequency EM (LFEM), and 24 with high-frequency EM (HFEM)] who received OnabotA in routine clinical practice in 2005–2015. In this study, the dosage regimen, the number of headaches, impact on quality of life (HIT-6 impact test) and the adverse events were among the parameters assessed.
OnabotA treatment significantly reduced the number of headaches experienced by CM and EM patients, also increasing the number of responders (> 50% reduction in headache days). The quality of life of EM patients improved significantly, reducing the HIT-6 scores in both LFEM and HFEM patients. Adverse events were reported in 40% of patients, always mild and transient.
OnabotA is an effective and safe prophylactic treatment for migraine in routine clinical practice. It significantly improves a patients’ quality of life, particularly that of those suffering from CM and HFEM.
Compliance with ethical standards
Conflict of interest
Writing and editorial assistance was provided by Dr Mark Sefton (BiomedRed SL) and funded by Allergan S.A. All authors met the ICMJE authorship criteria and received neither honoraria nor payments for authorship. None of the authors have any conflict of interest to declare.
All procedures involving human participants were performed in accordance with institutional and/or national research committee ethical standards and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all the participants in the study.
- 2.World Health Organization. headache disorders fact sheet no. 277, 2016. http://www.who.int/mediacentre/factsheets/fs277/en/.
- 3.World Health Organization. Lifting The burden, atlas of headache disorders and resources in the world 2011. http://www.who.int/mental_health/management/atlas_headache_disorders/en/.
- 17.BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Allergan, Irvine. 2013.Google Scholar
- 33.Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: table 1: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.CrossRefGoogle Scholar
- 39.Ezpeleta D, Rosich P, editors. Guía oficial de práctica clínica en cefaleas 2015. Guías Oficiales de la Sociedad Española de Neurología. 5th ed. Madrid: Luzán; 2015.Google Scholar
- 41.Rothrock JK, Scanlon C, Weibelt S. OnabotulinumtoxinA for the treatment of chronic migraine: long-term outcome [abstract]. In: American Headache Association Meeting; 2011.Google Scholar
- 43.Blumenfeld AM, Aurora SK, Laranjo K, et al. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15:100. https://doi.org/10.1186/s12883-015-0353-x.CrossRefPubMedPubMedCentralGoogle Scholar